Camille L Bedrosian is EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 46,720 shares of RARE, which is worth approximately $1.96 Million. The most recent transaction as insider was on Mar 01, 2023, when has been sold 3,881 shares (Common Stock) at a price of $45.25 per share, resulting in proceeds of $175,615. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.7K
0% 3M change
0% 12M change
Total Value Held $1.96 Million

Camille L Bedrosian Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 01 2023
SELL
Open market or private sale
$175,615 $45.25 p/Share
3,881 Reduced 7.67%
46,720 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
2,663 Added 5.0%
50,601 Common Stock
Mar 01 2022
SELL
Open market or private sale
$187,935 $66.62 p/Share
2,821 Reduced 7.67%
33,938 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
14,000 Added 22.6%
47,938 Common Stock
Jan 30 2022
SELL
Open market or private sale
$109,859 $66.3 p/Share
1,657 Reduced 4.31%
36,759 Common Stock
Oct 14 2021
SELL
Open market or private sale
$29,129 $81.14 p/Share
359 Reduced 0.93%
38,416 Common Stock
Sep 02 2021
SELL
Open market or private sale
$250,450 $100.18 p/Share
2,500 Reduced 6.06%
38,775 Common Stock
Sep 02 2021
BUY
Exercise of conversion of derivative security
$137,500 $55.0 p/Share
2,500 Added 5.71%
41,275 Common Stock
Sep 01 2021
SELL
Open market or private sale
$250,075 $100.03 p/Share
2,500 Reduced 6.06%
38,775 Common Stock
Sep 01 2021
BUY
Exercise of conversion of derivative security
$137,500 $55.0 p/Share
2,500 Added 5.71%
41,275 Common Stock
May 06 2021
SELL
Open market or private sale
$41,376 $113.67 p/Share
364 Reduced 0.93%
38,775 Common Stock
Apr 15 2021
SELL
Open market or private sale
$545,450 $109.09 p/Share
5,000 Reduced 11.33%
39,139 Common Stock
Apr 15 2021
BUY
Exercise of conversion of derivative security
$275,000 $55.0 p/Share
5,000 Added 10.18%
44,139 Common Stock
Mar 01 2021
SELL
Open market or private sale
$627,752 $138.18 p/Share
4,543 Reduced 10.4%
39,139 Common Stock
Mar 01 2021
BUY
Grant, award, or other acquisition
-
10,136 Added 18.83%
43,682 Common Stock
Jan 30 2021
SELL
Open market or private sale
$314,827 $140.36 p/Share
2,243 Reduced 6.27%
33,546 Common Stock
Jan 15 2021
SELL
Open market or private sale
$3,479,500 $139.18 p/Share
25,000 Reduced 41.13%
35,789 Common Stock
Jan 15 2021
BUY
Exercise of conversion of derivative security
$1,375,000 $55.0 p/Share
25,000 Added 29.14%
60,789 Common Stock
Oct 14 2020
SELL
Open market or private sale
$23,056 $88.0 p/Share
262 Reduced 0.73%
35,789 Common Stock

Also insider at

CRNX
Crinetics Pharmaceuticals, Inc. Healthcare
RYTM
RHYTHM PHARMACEUTICALS, INC. Healthcare
AMLX
Amylyx Pharmaceuticals, Inc. Healthcare
CLB

Camille L Bedrosian

EVP and Chief Medical Officer
San Diego, CA

Track Institutional and Insider Activities on RARE

Follow Ultragenyx Pharmaceutical Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE